Emmett M. Leddin

Emmett M. Leddin

Auto-generated profile, based on publicly available information

Emmett M. Leddin

Department of Chemistry, University of North Texas, Denton, Texas 76201, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AYAnna Yeaton
Anna Yeaton
GCGeraldine Cayanan
Geraldine Cayanan
SLSanam Loghavi
Sanam Loghavi
IDIgor Dolgalev
Igor Dolgalev
ELEmmett M. Leddin
Emmett M. Leddin
MGMaria Guillamot
Maria Guillamot
Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated preleukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation frequently found in patients with CH and leukemia. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid leukemia (AML). Using single-cell transcriptomic profiling of the bone marrow, we show that disease progression in aged animals correlates with an enhanced inflammatory response and the emergence of an aberrant inflammatory monocytic cell population. The gene signature characteristic of this inflammatory population is associated with poor prognosis in patients with AML. Our study illustrates an example of collaboration between a genetic lesion found in CH and inflammation, leading to transformation and the establishment of blood neoplasms. Significance: Progression from a preleukemic state to transformation, in the presence of TET2 mutations, is coupled with the emergence of inflammation and a novel population of inflammatory monocytes. Genes characteristic of this inflammatory population are associated with the worst prognosis in patients with AML. These studies connect inflammation to progression to leukemia. See related commentary by Pietras and DeGregori, p. 2234 . This article is highlighted in the In This Issue feature, p. 2221

2 November 2018 in Biochemistry
Verified
Journal Article
Closed access
JDJamie E. DeNizio
Jamie E. DeNizio
MLMonica Yun Liu
Monica Yun Liu
ELEmmett M. Leddin
Emmett M. Leddin
G. Andrés CisnerosG. Andrés Cisneros
G. Andrés Cisneros
RKRahul M. Kohli
Rahul M. Kohli

18 April 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SNSehr Naseem-Khan
Sehr Naseem-Khan
MBMadison B. Berger
Madison B. Berger
ELEmmett M. Leddin
Emmett M. Leddin
YMYazdan Maghsoud
Yazdan Maghsoud
G. Andrés CisnerosG. Andrés Cisneros
G. Andrés Cisneros


13 July 2018 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
NANicole M. Antczak
Nicole M. Antczak
AWAlice R. Walker
Alice R. Walker
HSHannah R. Stern
Hannah R. Stern
ELEmmett M. Leddin
Emmett M. Leddin
CPCarl Palad
Carl Palad
PBPenny Beuning
Penny Beuning

20 December 2022 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
ISIrving Simonin-Wilmer
Irving Simonin-Wilmer
RORaul Ossio
Raul Ossio
ELEmmett M Leddin
Emmett M Leddin
MHMark Harland
Mark Harland
KPKaren A Pooley
Karen A Pooley
CRCarla Daniela Robles-Espinoza
Carla Daniela Robles-Espinoza
Pathogenic germline variants in the protection of telomeres 1 gene (POT1) have been associated with predisposition to a range of tumour types, including melanoma, glioma, leukaemia and cardiac angiosarcoma. We sequenced all coding exons of the POT1 gene in 2928 European-descent melanoma cases and 3298 controls, identifying 43 protein-changing genetic variants. We performed POT1-telomere binding assays for all missense and stop-gained variants, finding nine variants that impair or disrupt protein–telomere complex formation, and we further define the role of variants in the regulation of telomere length and complex formation through molecular dynamics simulations. We determine that POT1 coding variants are a minor contributor to melanoma burden in the general population, with only about 0.5% of melanoma cases carrying germline pathogenic variants in this gene, but should be screened in individuals with a strong family history of melanoma and/or multiple malignancies.